Which Neoadjuvant Treatment Strategy for High-Risk Resectable Melanoma?
NeoCombi and OpACIN-neo point to a critical assessment of patterns of relapse to two neoadjuvant treatment approaches
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
NeoCombi and OpACIN-neo point to a critical assessment of patterns of relapse to two neoadjuvant treatment approaches
An update on the registration-enabling ARROW study
Efficacy was investigated in patients who had disease progression on or after two or more prior lines of therapy and enrolled in the KEYNOTE-158 Cohort G or KEYNOTE-028 Cohort C1
Latest data from KEYNOTE-001 study provide the longest efficacy/safety follow-up in this setting
Long terms outcomes in BRAF V600-mutated unresectable or metastatic melanoma
Review of handling errors with depot formulations of leuprorelin medicines
Approval is based on Study GO29365 that included a cohort of patients with relapsed or refractory diffuse large B-cell lymphoma after at least one prior regimen
KEYNOTE-062 shows that front-line pembrolizumab may be promising alternative to chemotherapy
FDA also expanded the intended use for the PD-L1 IHC 22C3 pharmDx kit to include use as a companion diagnostic for selecting patients with HNSCC
Shifts in microbiome and metabolome occur early in colorectal cancer development
Combinations of immune checkpoint inhibitor and targeted therapies show tolerability and promising efficacy
Approval is based on evidence from AUGMENT and MAGNIFY trials
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.